Free Trial

Vor Biopharma (VOR) Competitors

Vor Biopharma logo
$31.28 +3.35 (+11.99%)
As of 04:00 PM Eastern

VOR vs. URGN, TSHA, PROK, IOVA, RAPP, PHAT, IMNM, PRAX, AVXL, and SANA

Should you be buying Vor Biopharma stock or one of its competitors? The main competitors of Vor Biopharma include Urogen Pharma (URGN), Taysha Gene Therapies (TSHA), ProKidney (PROK), Iovance Biotherapeutics (IOVA), Rapport Therapeutics (RAPP), Phathom Pharmaceuticals (PHAT), Immunome (IMNM), Praxis Precision Medicines (PRAX), Anavex Life Sciences (AVXL), and Sana Biotechnology (SANA). These companies are all part of the "pharmaceutical products" industry.

Vor Biopharma vs. Its Competitors

Vor Biopharma (NASDAQ:VOR) and Urogen Pharma (NASDAQ:URGN) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, profitability, media sentiment, analyst recommendations, risk and institutional ownership.

Vor Biopharma has a beta of 2.05, meaning that its stock price is 105% more volatile than the S&P 500. Comparatively, Urogen Pharma has a beta of 1.1, meaning that its stock price is 10% more volatile than the S&P 500.

Vor Biopharma has a net margin of 0.00% compared to Urogen Pharma's net margin of -164.44%. Vor Biopharma's return on equity of 0.00% beat Urogen Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Vor BiopharmaN/A N/A N/A
Urogen Pharma -164.44%-97,487.15%-59.38%

Vor Biopharma has higher earnings, but lower revenue than Urogen Pharma. Urogen Pharma is trading at a lower price-to-earnings ratio than Vor Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vor BiopharmaN/AN/AN/A-$273.20-0.11
Urogen Pharma$90.40M9.15-$126.87M-$3.32-5.39

Urogen Pharma has a consensus price target of $32.00, indicating a potential upside of 78.97%. Given Urogen Pharma's higher possible upside, analysts plainly believe Urogen Pharma is more favorable than Vor Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vor Biopharma
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
3.00
Urogen Pharma
0 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
3.00

97.3% of Vor Biopharma shares are held by institutional investors. Comparatively, 91.3% of Urogen Pharma shares are held by institutional investors. 0.5% of Vor Biopharma shares are held by company insiders. Comparatively, 4.7% of Urogen Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Vor Biopharma had 3 more articles in the media than Urogen Pharma. MarketBeat recorded 4 mentions for Vor Biopharma and 1 mentions for Urogen Pharma. Urogen Pharma's average media sentiment score of 1.78 beat Vor Biopharma's score of -0.50 indicating that Urogen Pharma is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Vor Biopharma
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Negative
Urogen Pharma
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

Summary

Vor Biopharma beats Urogen Pharma on 7 of the 13 factors compared between the two stocks.

Get Vor Biopharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for VOR and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VOR vs. The Competition

MetricVor BiopharmaBiological Products, Except Diagnostic Substances IndustryManufacturing SectorNASDAQ Exchange
Market Cap$176.95M$241.80M$2.55B$10.52B
Dividend YieldN/AN/A2.49%4.57%
P/E Ratio-0.11N/A26.4326.62
Price / SalesN/A353.86243.90119.62
Price / CashN/AN/A51.2461.85
Price / BookN/A2.8933.216.45
Net IncomeN/A-$111.70M$14.12M$271.57M
7 Day Performance-0.38%2.47%0.73%2.83%
1 Month Performance-27.93%-35.53%3.71%7.27%
1 Year PerformanceN/A88.43%17.51%26.07%

Vor Biopharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VOR
Vor Biopharma
0.2031 of 5 stars
$31.28
+12.0%
N/AN/A$176.95MN/A-0.11140News Coverage
Stock Split
Gap Down
URGN
Urogen Pharma
4.1363 of 5 stars
$18.79
-2.4%
$32.00
+70.3%
+32.9%$890.59M$90.40M-5.66200Positive News
TSHA
Taysha Gene Therapies
2.122 of 5 stars
$3.07
-5.2%
$8.29
+169.9%
+33.5%$883.86M$8.10M-9.03180
PROK
ProKidney
3.4828 of 5 stars
$2.48
-16.8%
$6.25
+152.0%
+14.2%$876.96M$80K-4.353High Trading Volume
IOVA
Iovance Biotherapeutics
4.3083 of 5 stars
$2.27
-6.2%
$11.90
+424.2%
-79.1%$875.69M$164.07M-1.85500
RAPP
Rapport Therapeutics
3.0498 of 5 stars
$23.76
+2.4%
$31.00
+30.5%
+23.0%$867.19MN/A-9.50N/A
PHAT
Phathom Pharmaceuticals
2.4607 of 5 stars
$11.84
-1.8%
$17.50
+47.8%
-36.3%$855.59M$114.04M-2.50110
IMNM
Immunome
2.1534 of 5 stars
$9.21
-4.9%
$22.89
+148.5%
-34.8%$842.60M$12.59M-2.9940News Coverage
Analyst Forecast
High Trading Volume
PRAX
Praxis Precision Medicines
2.2535 of 5 stars
$37.71
-4.3%
$85.88
+127.7%
-21.4%$829.79M$7.77M-3.07110Positive News
AVXL
Anavex Life Sciences
3.8407 of 5 stars
$9.37
-2.2%
$44.00
+369.6%
+55.0%$822.86MN/A-16.4440
SANA
Sana Biotechnology
2.9678 of 5 stars
$3.22
-5.3%
$8.00
+148.4%
-23.5%$808.54MN/A-3.04380

Related Companies and Tools


This page (NASDAQ:VOR) was last updated on 9/23/2025 by MarketBeat.com Staff
From Our Partners